jefferies' michael yee explains his top biotech picks: vrtx, fate, zlab
Published 2 years ago • 3.2K plays • Length 2:57Download video MP4
Download video MP3
Similar videos
-
5:00
jefferies michael yee explains why he is bullish on biotech in 2022
-
4:18
biotech stocks have been overlooked for the past year and a half, says jefferies' michael yee
-
5:52
biotech boom ahead in 2024, top jefferies analyst predicts on heels of bristol meyers-karuna deal
-
5:58
we see big pharma going after smaller biotechs in 2024, says jefferies' michael yee
-
3:20
jefferies' michael yee expects big opportunities for a.i. in the biotech sector
-
51:01
how does big tech shake up the payments industry? | fintech insider insights podcast | 752
-
3:02
iflix is much more than the netflix of asia
-
5:32
these are the stocks to buy for the next 10 years
-
3:33
jefferies' michael yee still likes amgen in the biotech sector
-
2:46
biotech will face challenges this year, says jefferies' michael yee
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
2:36
the biggest wave of covid injections are behind us, says jefferies' michael yee
-
3:34
pharma could see a wave of m&a activity in 2024, says jefferies' michael yee
-
2:29
you can start to dip your toes into biotech here, says jefferies' yee
-
5:02
what investors should look for in biotech stocks
-
24:25
hidden gems in tech that investors need to know: opening bid
-
4:09
biotech remains a strong opportunity for 2021: jefferies' michael yee
-
4:10
buy or bail on biotech: here's what you need to know
-
4:52
pce data was 'the best one can expect': economist
-
3:46
jefferies' michael yee on biogen as fda could be on the verge of approving alzheimer's drug
-
4:31
jefferies' michael yee expects amgen's horizon therapeutics deal will go through despite ftc block
-
2:31
we still think there's more room for biotech to go higher, says jefferies' yee